A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL
88998377LYM1001
Phase 1 other active
Quick answer
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL for relapsed or refractory B‑cell non-Hodgkin lymphomas is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- relapsed or refractory B‑cell non-Hodgkin lymphomas
- Phase
- Phase 1
- Modality
- other
- Status
- active